ORTHO-NOVUM 7/7/7-21 Drug Patent Profile

Which patents cover Ortho-novum 7/7/7-21, and when can generic versions of Ortho-novum 7/7/7-21 launch?

Ortho-novum 7/7/7-21 is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in ORTHO-NOVUM 7/7/7-21 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Summary for ORTHO-NOVUM 7/7/7-21

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Patent Applications:	238
DailyMed Link:	ORTHO-NOVUM 7/7/7-21 at DailyMed

US Patents and Regulatory Information for ORTHO-NOVUM 7/7/7-21

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	ORTHO-NOVUM 7/7/7-21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018985-001	Apr 4, 1984		DISCN	No	No

Expired US Patents for ORTHO-NOVUM 7/7/7-21

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	ORTHO-NOVUM 7/7/7-21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018985-001	Apr 4, 1984	4,530,839
Janssen Pharms	ORTHO-NOVUM 7/7/7-21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018985-001	Apr 4, 1984	4,544,554
Janssen Pharms	ORTHO-NOVUM 7/7/7-21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018985-001	Apr 4, 1984	4,628,051
Janssen Pharms	ORTHO-NOVUM 7/7/7-21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018985-001	Apr 4, 1984	4,616,006

International Patents for ORTHO-NOVUM 7/7/7-21

See the table below for patents covering ORTHO-NOVUM 7/7/7-21 around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1226221	ANTI-PROGRESTATIF TRIPHASE POUR ADMINISTRATION PAR VOIE ORALE (TRIPHASIC ORAL CONTRACEPTIVE)

Supplementary Protection Certificates for ORTHO-NOVUM 7/7/7-21

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1214076	SZ 49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON

Market Dynamics and Financial Trajectory for ORTHO-NOVUM 7/7/7-21

Last updated: February 20, 2026

What is the current market landscape for oral contraceptives like ORTHO-NOVUM 7/7/7-21?

ORTHO-NOVUM 7/7/7-21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone, marketed by Bausch Health. Its market sits within the broader $8 billion global oral contraceptives segment [1]. The segment has experienced steady growth driven by increasing acceptance, regulatory approvals, and expanding healthcare coverage.

Major competitors include generic versions, other branded oral contraceptives such as Yaz, Loestrin, and Ortho Tri-Cyclen, along with newer forms like hormonal patches and intrauterine devices (IUDs).

In the U.S., oral contraceptives account for 54% of all contraceptive use [2]. Sales are influenced by women’s healthcare trends, legal environment, and insurance coverage changes.

How do regulatory and patent issues influence market prospects?

Orthoe-NOVUM 7/7/7-21's patent protection ended in the early 2000s, leading to a surge in generic competition. Generic versions now capture a significant share, reducing branded product revenues.

Regulatory agencies like the FDA continue to enforce safety standards. Any new formulations must demonstrate safety and efficacy for approval, limiting market expansion to reformulations or indications.

What are the key drivers impacting the financial trajectory?

Market Penetration and Competition: Competition from generics erodes margins. However, branded versions like ORTHO-NOVUM 7/7/7-21 maintain stable revenues through brand loyalty, prescriber preference, and targeted marketing.

Pricing Strategies: Price erosion is common due to generics. Branded products often rely on differentiated marketing and patient support programs to sustain premiums.

Healthcare Policy and Coverage: Insurance coverage impacts sales volume. Legislation favouring contraceptive access enhances market size. The Affordable Care Act's mandate for contraceptive coverage increased demand until recent policy shifts.

Consumer Trends: Increasing awareness and acceptance of oral contraceptives support stable demand. Shift toward multi-month prescriptions reduces visit frequency but stabilizes sales.

Product Line Expansion: Development of fixed-dose combinations and prolonged-release formulations could provide revenue gains. However, innovation faces regulatory hurdles and competition from alternative contraceptive methods.

What is the revenue outlook for ORTHO-NOVUM 7/7/7-21?

Given patent expiry, revenues from ORTHO-NOVUM 7/7/7-21 are unlikely to grow substantially in the near term. The product's mature status and competition from generics cap growth potential.

Estimates suggest current global sales at approximately $120 million annually, primarily driven by established markets. The U.S. market represents about 60% of sales, with remaining revenue from Europe and parts of Asia.

Future revenues depend on:

• Maintaining prescriber preference.
• Price management against generics.
• Expanding indications or formulations.

If the drug maintains its market share, revenues could remain stable for the next 3-5 years. Launching reformulated versions or expanding into emerging markets may offer incremental gains but will involve regulatory and marketing investments.

How will market trends affect the long-term prospects?

Increasing adoption of alternative contraceptive methods, such as IUDs and implants, may reduce oral contraceptive sales long-term. However, the established patient base and brand recognition provide ongoing revenue streams.

Market shifts towards non-hormonal options and concerns about hormone-related side effects could impair demand. Conversely, growing contraception needs in emerging markets present opportunities for incremental revenue growth through strategic expansion.

Regulatory restrictions or insurance coverage changes could also impact sales volume and pricing policies.

Summary of financial trajectory

Scenario	Revenue Impact	Key Factors
Status quo	Stable, modest decline	Generics, competitive pressure
Market expansion in emerging markets	Moderate growth	Regulatory hurdles, market access
Product innovation	Potential upside	Reformulations, new formulations
Regulatory tightening	Revenue decline	Restrictions on hormonal contraceptives

Key Takeaways

• ORTHO-NOVUM 7/7/7-21 faces a mature market with declining branded sales due to generic competition.
• Revenue stability hinges on prescriber loyalty and market penetration.
• Growth opportunities are limited but exist through geographic expansion and product reformulation.
• Long-term prospects depend on market trends, regulatory landscape, and consumer preferences.
• The product's financial contribution remains significant primarily in legacy markets, with incremental growth unlikely without innovation.

FAQs

1. Will ORTHO-NOVUM 7/7/7-21 regain market share?
Unlikely without repositioning or reformulation, due to widespread generic competition.

2. How does generic competition affect the product’s pricing?
Generic entry drives prices downward, reducing profit margins for branded versions.

3. Are there regulatory barriers to expanding this product line?
Yes; new formulations need FDA approval, which involves clinical trials and safety assessments.

4. What emerging markets could present growth opportunities?
Markets in Southeast Asia and Latin America expanding contraceptive access may offer potential.

5. What impact could new contraceptive technologies have on this product?
Shift towards non-hormonal and long-acting methods could reduce oral contraceptive demand over time.

---

References

[1] IMS Health. (2022). Global Market Data for Oral Contraceptives.
[2] U.S. Centers for Disease Control and Prevention. (2022). Contraceptive Use in the United States.